Status:
RECRUITING
Molecular Signature From Tumor to Lymph Nodes
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
National Cancer Institute, France
Ministry of Health, France
Conditions:
Lung Cancer
Stage IIIA-cN2
Eligibility:
All Genders
18+ years
Brief Summary
Mediastinal lymph node (LN) involvement (N2) in non-small cell lung cancer (NSCLC) concerns 15% of resectable tumors and is associated with a poor prognosis and an overall survival reaching 9 to 49%. ...
Detailed Description
We planned a comprehensive molecular characterization of tumors and lymph nodes to evaluate the impact of molecular signatures and molecular heterogeneity on disease-free survival after surgery in III...
Eligibility Criteria
Inclusion
- Adult patient, men and women age \>18 years
- Patients operated with a curative intent for an IIIA-cN2 NSCLC
- Social security affiliation
- Written informed consent for patient included in part 2 (prospective) or not opposing the use of this data for patient included in part 1 (retrospective)
Exclusion
- Patient with T4, R1 or R2 surgical resection, sublobar resection, no radical lymphadenectomy
- Patient under protectives measures
- Pregnancy or breast-feeding
Key Trial Info
Start Date :
March 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04677205
Start Date
March 30 2021
End Date
November 1 2027
Last Update
January 9 2023
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital du Haut-Lévêque, CHU de Bordeaux
Bordeaux, France
2
Hôpital Militaire Percy
Clamart, France
3
Hôpital Nord
Marseille, France
4
Hôpital Pasteur, CHU de Nice
Nice, France